Timing of ARSI and taxanes for mCRPC
Timing of ARSI and taxanes for mCRPC
In this podcast Assoc. Prof. Tanya Dorff and Dr Neal Shore focus on patients with metastatic castration-resistant prostate cancer (mCRPC) and discuss when to use androgen receptor signaling inhibitors (ARSI) and taxanes for these patients.
In this podcast Assoc. Prof. Tanya Dorff and Dr Neal Shore focus on patients with metastatic castration-resistant prostate cancer (mCRPC) and discuss when to use androgen receptor signaling inhibitors (ARSI) and taxanes for these patients.
Assoc. Prof. Tanya Dorff, Dr. Neal Shore
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Dr. Neal Shore
Urologist
Carolina Urologic Research Center and GenesisCare
United States (US)
Podcast | 
30 min
|
Jun 2022
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
<ADD TRANSCRIPT>
Podcast: Timing of androgen receptor signaling inhibitors (ARSI) and taxanes for metastatic castration-resistant prostate cancer (mCRPC)
In this podcast Assoc. Prof. Tanya Dorff and Dr Neal Shore focus on patients with mCSPC and discuss when to use ARSI and taxanes for these patients.
This GU CONNECT podcast is also available on
AstraZeneca
Other programmes of interest
28 min
Other programmes developed by Assoc. Prof. Tanya Dorff
Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
